

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Xunfei Healthcare Technology Co., Ltd.

訊飛醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2506)

VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION WITH RIMAG

This announcement is made voluntarily by Xunfei Healthcare Technology Co., Ltd. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) for the purpose of informing the shareholders of the Company and potential investors of the latest business development of the Group.

The board of directors of the Company (the “**Board**”) hereby announces that, in order to achieve common prosperity and mutual benefits with win-win results, the Company and Jiangxi Rimag Group Co., Ltd. (the “**Rimag**”, the H shares of which are listed on The Stock Exchange of Hong Kong Limited, stock code: 2522), based on their strengths and resources in their respective fields, have recently entered into a strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) after friendly negotiations.

Pursuant to the Strategic Cooperation Agreement, the Company and Rimag are planning to commence cooperation in the following areas: (i) to carry out joint business and market development in the advantageous regions of both parties, and to jointly deepen the development of smart healthcare for grassroots level, close-knit medical consortiums and regional medical sharing centers; (ii) to achieve in-depth cooperation in respect of core products and business models of both parties, and to develop complementary businesses and realise synergies; (iii) to jointly design and explore innovative smart healthcare business investment models, and to explore applicable and replicable business models especially in the construction, operation, and management of a regional healthcare trusted data space as well as in industry monetisation; (iv) to conduct collaborative research and development, promotion and market application of medical vertical cognitive large models and medical imaging AI diagnostic large models; and (v) to jointly explore and develop smart healthcare management, chronic disease management, and post-hospital management of patients, etc., combining online smart healthcare management with offline physical examination, imaging, pathology, and electrocardiography.

Rimag, a leading medical group specializing in medical imaging in China, is the operator and manager of a medical imaging platform that provides comprehensive medical imaging services and value to the entire medical imaging industry chain, with its main businesses including the provision of imaging center services, imaging solution services and Rimag Cloud services. The Group is an AI-empowered healthcare solution provider, offering products and solutions that support a range of healthcare services, from health risk warnings, early screening, auxiliary diagnosis and treatment, as well as treatment effect evaluation to post-discharge management and chronic disease management.

The directors of the Company are of the view that the Strategic Cooperation Agreement was entered into in the ordinary and usual course of business of the Group on terms that are fair and reasonable, on normal commercial terms or better terms and in the interests of the Company and its shareholders as a whole. This cooperation is not only an in-depth integration of technology and resources between the two parties, but also an innovative breakthrough in the deep synergy between medical AI enterprises and medical imaging service providers, achieving the industrial integration from technology complementation, scenario interconnection to ecological co-construction. With the gradual deepening of the cooperation, the Company and Rimag are promoting the accelerated formation of a more efficient and fairer intelligent medical ecosystem with the dual logic of “technological revolution + ecological win-win”, and injecting new kinetic energy into the strategy of Healthy China.

By order of the Board
Xunfei Healthcare Technology Co., Ltd.
Dr. Tao Xiaodong
Executive Director

Hong Kong, February 19, 2025

As of the date of this announcement, the Board of the Company comprises: (i) Dr. Tao Xiaodong as executive director; (ii) Dr. Liu Qingfeng, Mr. Zhao Zhiwei and Mr. Duan Dawei as non-executive directors; and (iii) Prof. Wang Yang, Prof. Zhao Huiyang and Mr. Tan Ching as independent non-executive directors.